Clinical characteristics, treatment and outcome of pembrolizumab-induced acute pancreatitis
Investigational New Drugs · 2024
DOI: 10.1007/s10637-024-01452-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Investigational New Drugs, 2024. Verfasst von Panpan Luo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Spine Surgery, The First Hospital of Hunan University of Chinese Medicine, Changsha, 410007, Hunan, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Pancreatitis. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Natural Science Foundation of Hunan Province.
Abstract (Originalsprache)
Acute pancreatitis (AP) is a rare adverse event of pembrolizumab with unclear clinical features. This study investigated the clinical features of pembrolizumab-induced AP to provide a reference for prevention and treatment. Case reports, case series and clinical studies of pembrolizumab-induced AP were collected by searching Chinese and English databases up to January 31, 2024. Thirty-one patients were included, with a median age of 59 years (range 39, 82). The median time from administration to onset of AP was 5.05 months (range 0.5, 16) and the median cycle was 7 cycles (range 1, 35). Twenty-two (71.0%) patients had elevated pancreatic amylase with a median value of 860 IU/L (range 105-12562), and 16 (51.6%) patients had elevated lipase with a median value of 282 IU/L (range 153-1034). Pancreatic biopsy showed neutrophil infiltration (9.7%) and lymphocyte infiltration (6.5%). Immunohistochemical staining showed CD8 dominated inflammatory infiltration (6.5%). The computed tomography showed diffuse enlargement (51.6%) and focal enlargement (51.6%) of the pancreas. Endoscopic ultrasound showed enlarged hypoechoic pancreas(16.1%). PET/CT showed increased FDG uptake (16.1%). The magnetic resonance cholangial pancreatography showed narrowing of main pancreatic duct (12.9%). AP symptoms and pancreatic enzymes improved after discontinuation of pembrolizumab and administration of steroids and infliximab. Clinicians should be aware that AP is a rare adverse reaction to pembrolizumab. Pembrolizumab induced AP can be initiated with steroids for control, and infliximab can be initiated with steroid-refractory AP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Spine Surgery, The First Hospital of Hunan University of Chinese Medicine, Changsha, 410007, Hunan, China.
- College of pharmacy, Changsha Medical University, Changsha, 410219, Hunan, China.
- Department of pharmacy, The First Hospital of Hunan University of Chinese Medicine, No.95 Shaoshan Middle Road, Changsha, 410007, Hunan, China. xy3yy202102@126.com.
- Department of pharmacy, The Third Xiangya Hospital, Central South University, No. 138 Tongzipo Road, YueLu District, Changsha, 410013, Hunan, China. wongcj@csu.edu.cn.
Förderung
- Natural Science Foundation of Hunan Province
Zitieren
APA
Luo, P., Guo, Y., He, Y., & Wang, C. (2024). Clinical characteristics, treatment and outcome of pembrolizumab-induced acute pancreatitis. Investigational New Drugs. https://doi.org/10.1007/s10637-024-01452-0
Vancouver
Luo P, Guo Y, He Y, Wang C. Clinical characteristics, treatment and outcome of pembrolizumab-induced acute pancreatitis. Investigational New Drugs. 2024. doi:10.1007/s10637-024-01452-0
BibTeX
@article{Luo2024,
author = {Luo, Panpan and Guo, Yuge and He, Yang and Wang, Chunjiang},
title = {Clinical characteristics, treatment and outcome of pembrolizumab-induced acute pancreatitis},
journal = {Investigational New Drugs},
year = {2024},
doi = {10.1007/s10637-024-01452-0}
}
EUVIMED